UK Medicines Information
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator
Information type:
Other primary research
Source:
The Lancet Neurology
Specialities:
Neurological disorders
Summary
Cohort data (n= 4137) reported that interferon beta and glatiramer acetate result in a 24–40% reduction in disability progression in relapsing-remitting MS and are cost effective (target of £36 000/QALY) over a 6 year follow-up period when modelled over a 20 year trajectory.
UKMi comment
A related commentary discusses these study findings.
Related links:
Comment
NICE CG186
NICE TA32